Months after an antitrust lawsuit challenged its deal with Sanofi and raised uncertainty about the future of MZE001, Maze secured a new partner for potentially the first oral Pompe disease drug.

A more than 70% stock slide shows that investors are concerned about three as-yet unexplained deaths in a Phase II study of the US firm’s lead candidate.

Bayer Consumer Health's recently established Precision Health unit launches its Aspirin Heart Risk Assessment tool in Saudi Arabia. Developed in partnership with British medtech firm Huma Therapeutics, Bayer is planning to roll out the digital tool to other countries in the Middle East and also Latin America. 

While Lupin is “truly excited with the potential” ahead, the uncertainty around upcoming product launches paints a different financial picture.